The Design of a Chimeric Antigen Receptor
Cameron J. Turtle, MD, PhD, from the Fred Hutchinson Cancer Research Center, discusses the design of a chimeric antigen receptor (CAR).
Cameron J. Turtle, MD, PhD, Assistant Member, Fred Hutchinson Cancer Research Center, Assistant Professor, University of Washington, discusses the design of a chimeric antigen receptor (CAR).
There are multiple ways to design a CAR and several components need to be considered: single-chain variable fragments (scFv), intracellular costimulatory and signaling molecules, and transmembrane domains of the spaces in between. In looking at different studies in mice or in the lab, one can see difference in the effects of different types of CARs.
In the case of a new target tumor antigen and a new scFv, optimization studies must take place to determine the right parameters for that tumor antigen. Tumor antigens may even differ in the type of cells being engineered or the type of patients being treated.
Clinical Pearls
Turtle says that not one design will be optimal for every type of CAR.
- Components to a CAR include: scFv, intracellular costimulatory and signaling molecules, and the transmembrane domains of the spaces
- In the case of a new target tumor antigen and a new scFv, optimization studies must take place to determine the right parameters
- Not one design will be optimal for every type of CAR
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
December 16th 2024The FDA granted breakthrough therapy designation to dostarlimab for locally advanced dMMR/MSI-H rectal cancer, highlighting its 100% clinical complete response rate in a phase 2 study.
Read More
